Requiring a pharmacist, or the pharmacist's designee who is under certain supervision, to inform a consumer of the availability of a therapeutically equivalent brand name drug that is the lowest cost alternative to the originally prescribed drug or device and the cost difference between the equivalent drug or device and the prescribed drug; requiring a pharmacist to provide written notice, or to maintain a record that indicates a patient was notified in writing or orally, that the generic product is equivalent to the brand name product; etc.
Bill File Type: Regular
Effective Date(s): October 1, 2021
HistoryToggle History Dropdown
File CodeToggle Filecode Dropdown
SubjectsToggle Subjects Dropdown
StatutesToggle Statutes Dropdown
Last Updated: 4/6/2021 4:22 PM